Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by R. Overland
Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
Molecular Cancer Therapeutics
Cancer Research
Oncology
Related publications
Nectin-Like Molecule-4/Cell Adhesion Molecule 4 Inhibits the Ligand-Induced Dimerization of ErbB3 With ErbB2
Scientific Reports
Multidisciplinary
Activated Akt1 Accelerates MMTV-c-ErbB2 Mammary Tumourigenesis in Mice Without Activation of ErbB3
Breast Cancer Research
Cancer Research
Oncology
Zinc Finger Transcription Factors Designed for Bispecific Coregulation of ErbB2 and ErbB3 Receptors: Insights Into ErbB Receptor Biology
Molecular and Cellular Biology
Cell Biology
Molecular Biology
Loss of Nrdp1 Enhances ErbB2/ErbB3-Dependent Breast Tumor Cell Growth
Cancer Research
Cancer Research
Oncology
Mutation of a SHC Binding Site Tyrosine Residue in ErbB3/HER3 Blocks Heregulin-Dependent Activation of Mitogen-Activated Protein Kinase
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
Mechanisms for DNA‑damaging Agent‑induced Inactivation of ErbB2 and ErbB3 via the ERK and P38 Signaling Pathways
Oncology Letters
Cancer Research
Oncology
Specificity and Heregulin Regulation of Ebp1 (ErbB3 Binding Protein 1) Mediated Repression of Androgen Receptor Signalling
British Journal of Cancer
Cancer Research
Oncology
The Anti-erbB3 Antibody MM-121/SAR256212 in Combination With Trastuzumab Exerts Potent Antitumor Activity Against Trastuzumab-Resistant Breast Cancer Cells
Molecular Cancer
Cancer Research
Oncology
Molecular Medicine
Driving Cancer Through ErbB3
Science-Business eXchange
